Positive Pivotal Ph 3 SIERRA Trial Results of Iomab-B Announced
Dr. Avinash Desai, Actinium’s Chief Medical Officer, commented, “Throughout the SIERRA trial, Actinium had a great partnership approach with BMT clinical trial sites, which has provided us with valuable insights for the potential commercial adoption and utilization of Iomab-B. Through our education efforts and shielding solutions, we have optimized administration of Iomab-B across a wide range of BMT centers. BMT centers are large, integrated hospitals that are accustomed to dealing with more complex procedures, such as surgeries or CAR-T cell therapy, and can administer single-infusion Iomab-B with relative ease compared to other complex cell therapies. The 24 BMT centers that participated in the SIERRA trial established a strong base that we will now look to build on in anticipation of Iomab-B commercial launch, assuming approval. On behalf of Actinium, I would like to thank all the nursing personnel at the SIERRA sites that made this first-of-its-kind trial possible.”
Share:
More News
“Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing
“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at
“Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” said Joseph Fiore, vice president, global program lead, repotrectinib, Bristol Myers
“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies,” said Prof. Ugur Sahin, M.D., Ph.D., CEO and co-founder of BioNTech. “We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors.
